Autopsy report · NCT05225558

A Phase 2a Study, Effect of Vancomycin With vs Without Delpazolid (LCB01-0371) in Patients With MRSA Bacteremia

Cause of deathSlow enrollment Automatic label, confidence 0.9, unverified. How labels are made.

“Early termination; Difficulties in enrolling subjects due to the decrease in patients with MRSA bacteremia”

The sponsor’s own words in the registry.

Life of this trial

Registered 3 months before it started.
Ran for about 1 year 11 months before it stopped.
40 participants enrolled.
Results were posted on the registry 1 year 2 months after it ended.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: LigaChem Biosciences, Inc.
Sponsor type: Industry
Conditions: MRSA Bacteremia
Interventions: Delpazolid; Vancomycin; Placebo of Delpazolid
Participants: 40
Sites: 6
Countries: South Korea

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.